The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230000, China
NCT Number: NCT07700082
This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC). We collected anonymized historical clinical data, preoperative gadoxetic acid-enhanced MRI scans and digital pathological whole-slide images from three Chinese medical centers and the public TCGA-LIHC database. We developed a multimodal hybrid deep learning prognostic model (named HCC-MPDS) integrating multi-source medical data to stratify HCC patients into high-risk and low-risk recurrence groups after surgery. The primary goal of this study is to compare postoperative recurrence-free survival (RFS) and overall survival (OS) between the two risk subgroups, and evaluate whether this artificial intelligence prediction system can help clinicians identify patients who may benefit from postoperative adjuvant therapy. No new experimental drugs or interventional treatments were provided to participants; all data were retrospectively extracted from archived medical records under institutional ethics approval, with waived written informed consent for de-identified historical samples and images.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hefei, Anhui, 230000, China
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Up to 60 months after hepatectomy
Time from surgical resection to first local/regional recurrence, distant metastasis or all-cause death, whichever occurs first
Anhui Provincial Hospital
Other Gov
Multimodal Hybrid Deep Learning-based Prognostic Decision System to Guide Adjuvant Therapy in Hepatocellular Carcinoma After Surgical Resection
Acronym: HCC-MPDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07562763
Adenocarcinoma, Adjuvant Therapy
Hefei, Anhu, China
View Trial DetailsNCT07687758
Adenocarcinoma, Blood-Borne Infections
Bangkok, Thailand
View Trial DetailsNCT02562755
Adenocarcinoma, Carcinoma
Birmingham, Alabama, United States
View Trial DetailsNCT04687969
Adenocarcinoma, Adenocarcinoma of Prostate
Boston, Massachusetts, United States
View Trial Details